logo-loader
viewCollagen Solutions PLC

Trading Update & Notice of Results

/**/ h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-top:2.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;line-height:107%;font-size:11.0pt;font-family:"Calibri Light","sans-serif";color:#2F5496;font-weight:normal;font-div:italic;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .av{size:612.0pt 792.0pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.av{}p.cc{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cd{color: black; font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.ce{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin: 0cm; margin-bottom: .0001pt; text-align: center}span.cf{font-size:11.0pt;font-family:"Calibri","sans-serif"; color:black}span.cg{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}p.ch{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin: 0cm; margin-bottom: .0001pt}span.bw{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:black}p.ci{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal} span.ar{}span.as{}span.cj{font-div: italic}p.ck{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif"; font-div: italic; line-height: normal; margin-bottom: 0cm; text-align: justify}span.bs{color:#212121}table.cl{width:490.5pt;margin-left:-5.4pt;border-collapse:collapse}td.bp{width:225.9pt; padding:0cm 5.4pt 0cm 5.4pt}p.cm{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;font-weight: bold; line-height: normal; margin-bottom: 0cm}td.bn{width:243.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.cn{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;margin-bottom:0cm;margin-bottom:.0001pt; line-height:normal} p.co{margin-top:0cm;margin-right:0cm;margin-bottom:10.0pt;margin-left:0cm;line-height:115%;font-size:11.0pt;font-family:"Calibri","sans-serif";color:#00000A;line-height: normal; margin-bottom: 0cm; text-align: right}td.bl{width:249.95pt; padding:0cm 5.4pt 0cm 5.4pt}td.bk{width:218.95pt;padding:0cm 5.4pt 0cm 5.4pt}td.bj{width:237.65pt; padding:0cm 5.4pt 0cm 5.4pt}td.bi{width:231.25pt; padding:0cm 5.4pt 0cm 5.4pt}td.bh{width:187.65pt;padding:0cm 5.4pt 0cm 5.4pt}td.be{width:281.25pt; padding:0cm 5.4pt 0cm 5.4pt}span.bg{color:#0070C0;text-decoration: none}span.bf{color:#0070C0}td.bd{border:none} p.cp{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;background:white}p.cq{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.cr{font-family: "Calibri","sans-serif"; font-size: 11.0pt; font-weight: bold}p.cs{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin:0cm;margin-bottom:.0001pt;text-align:justify}span.ct{font-size:11.0pt;font-family:"Calibri","sans-serif"}span.ax{font-size:11.0pt; font-family:"Calibri","sans-serif"}p.cu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:-22.3pt;margin-bottom: 0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;line-height:normal} /**/
RNS Number : 6124Q
Collagen Solutions PLC
22 October 2019
 

 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

 

Trading Update & Notice of Results

 

Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, provides an update on trading for the six months to 30 September 2019.

 

Revenue is expected to be £2.23m (H1 2018: £1.95m), representing a 14.4% increase on the prior year, driven in particular by continuing momentum in our newly established tissue business.

 

New customer acquisition continues with four new customer contracts and 10 new customers.

 

In June 2019, the Company completed a fundraise of £5.96m gross of costs made up of a strategic investment by Rosen's Diversified Inc of £4.18 million, a placing with existing and new investors of £1.25 million and an open offer totalling £0.53 million. The funds are being used to further customer and proprietary product development, expand contract manufacturing activities and capabilities and for working capital including the repayment of the Norgine Ventures Bond Facility.  

 

The Company continues to execute on its customer product development milestones, having signed new development customers, which represent additional future contract manufacturing opportunities, once these products are approved and launched. In addition, the Company remains engaged in the process to address questions from its notified body for the ChondroMimetic® CE mark consistent with our previously stated plans.

 

Jamal Rushdy, CEO, commented: "We are pleased to report the third consecutive six-month period of double-digit sales growth demonstrating consistent performance to our expectations by the Collagen Solutions global team. Our core business remains strong and our initiative to increase capacity is on track to meet the anticipated higher demand for both collagen and tissue products."

 

The Company will announce its interim results for the six months to 30 September 2019 on Tuesday, 3 December 2019.

 

Collagen Solutions Plc

 

Jamal Rushdy, CEO 

Via Walbrook

Hilary Spence, CFO

 

 

 

Cenkos Securities Plc (Nominated Adviser and Broker)

 

Giles Balleny (Corporate Finance)

Tel: 0207 397 8900

Max Gould

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected] 

Anna Dunphy

Mob: 07876 741 001

         

 

  

 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

 

For more information go to: www.collagensolutions.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCMBBATMBATBML

Quick facts: Collagen Solutions PLC

Price: 3.35

Market: LSE
Market Cap: £14.86 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Collagen Solutions reports strong growth in its tissue business in first half

Collagen Solutions PLC's (LON:COS) Jamal Rushdy and Hilary Spence update Proactive London's Andrew Scott on first half performance - their third consecutive six-month period of double-digit sales growth. Revenues increased by 14% to £2.23mln in the period ended September 30. Tissue sales more...

4 days, 21 hours ago

RNS

Half-year Report

4 days, 22 hours ago

Investor results presentation

2 weeks, 5 days ago

Directorate Change

3 weeks, 4 days ago

Result of AGM

on 28/8/19

AGM Statement

on 28/8/19